0001415889-24-007319.txt : 20240308
0001415889-24-007319.hdr.sgml : 20240308
20240308160431
ACCESSION NUMBER: 0001415889-24-007319
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240307
FILED AS OF DATE: 20240308
DATE AS OF CHANGE: 20240308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: THURMAN RANDY H
CENTRAL INDEX KEY: 0001204059
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 24734267
MAIL ADDRESS:
STREET 1: 222 MERCHANDISE MART PLAZA
STREET 2: SUITE 2024
CITY: CHICAGO
STATE: IL
ZIP: 60654
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4
1
form4-03082024_090322.xml
X0508
4
2024-03-07
0001649989
Outlook Therapeutics, Inc.
OTLK
0001204059
THURMAN RANDY H
C/O OUTLOOK THERAPEUTICS, INC.
485 ROUTE 1 SOUTH, BUILDING F, SUITE 320
ISELIN
NJ
08830
true
false
false
false
0
Stock Option (Right to Buy)
0.41
2024-03-07
4
A
0
94441
0
A
2034-03-07
Common Stock
94441
94441
D
The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
/s/ Lawrence Kenyon, Attorney-in-Fact
2024-03-08